Through long-term research, based on establishing the pharmacological, toxicological and pharmacokinetic studies of CHA, Jiuzhang Biotech has developed CHA, a Class 1 new drug in China, and its preparations. In cooperation with renowned universities, we have completed all the pre-clinical research work of this drug, including topic establishment, research on the preparation process of the bulk drug, structure confirmation research, quality research and formulation of quality standards, stability research, selection of packaging materials or containers in direct contact with the drug, research on dosage forms and formulation processes, pharmacology, pharmacodynamics, toxicology, pharmacokinetics, tests on allergic reactions, hemolysis and local irritation, tests on mutagenicity, reproductive toxicity, carcinogenicity, dependence, as well as pharmacokinetic studies, etc.

On this basis, we have designed the relationship between the in-vivo metabolites of CHA and the body's immunity, as well as the relationship with tumor growth; designed the binding relationship between CHA and the target and its binding type, and determined the relevant enzymes; revealed the relationship between CHA and the increase of white blood cells at the molecular level, and at the same time clarified the structure-activity relationship of CHA, providing a necessary theoretical basis for further structural optimization. We strive to develop new compounds with higher activity, lower toxicity and lower cost, which have independent intellectual property rights, based on the structure of CHA. We believe that in the near future, tumor diseases can be prevented and cured just like common diseases.

We are planning the further research, development and experiments of the above achievements, and completing the preliminary theoretical research and the determination of the arguments. At the same time, we introduce the concept of nanotechnology, and achieve the organic coordination in aspects such as molecular charge, the electromagnetic field of target organ cells, the weak biological electric field, cytokines, and the immune system in the microscopic world, so as to achieve a major breakthrough in life sciences and confirm the practical significance of the theory we proposed through clinical trials. Let the modified CHA molecules be directionally adsorbed on the surface of target organ cells, causing the orderly arrangement of CHA. The orderly arrangement of CHA will determine the orientation of the carboxyl group on the quinuclidine ring. The carboxyl group carries a negative charge, and after orientation, it will generate a weak electric field near the magnetic field of the target organ cells. The interaction between the two weak electric fields and the mutual influence of positive and negative charges can lead to the activation of cytokines, thus activating the dormant part of the human immune system and increasing the immune efficiency and recognition rate. Establishing a theoretical system of border sciences lays a solid foundation for completely conquering difficult and complicated diseases such as cancer, AIDS, diabetes, and hepatitis B. This is not only the wealth of our enterprise, but also the wealth of the country.

(Please indicate the source when reprinting)